PCM
MRNA icon

Prelude Capital Management’s Moderna MRNA Stock Holding History

Prelude Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,300
Closed -$413K – 1353
2022
Q4 		$413K Buy
+2,300
New +$376K 0.02% 641
2022
Q3 		– Sell
-4,400
Closed -$629K – 1800
2022
Q2 		$629K Sell
4,400
-100
-2% -$14.3K 0.02% 693
2022
Q1 		$775K Buy
4,500
+100
+2% +$16.8K 0.02% 683
2021
Q4 		$1.12M Sell
4,400
-1,200
-21% -$351K 0.03% 555
2021
Q3 		$2.15M Buy
+5,600
New +$2.07M 0.06% 277
2020
Q4 		– Sell
-400
Closed -$28K – 1722
2020
Q3 		$28K Sell
400
-4,000
-91% -$279K ﹤0.01% 1272
2020
Q2 		$283K Buy
4,400
+2,900
+193% +$159K 0.02% 631
2020
Q1 		$45K Buy
+1,500
New +$34.5K ﹤0.01% 781

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's MRNA Position: Q1 2026 in Review

Prelude Capital Management sold out of Moderna (MRNA) in Q1 2026, closing a stake of 7,095 shares — an estimated $209K sold.

Prelude Capital Management first reported a position in MRNA in Q4 2018 and held it in 7 quarters. The position peaked at $1.03M in Q4 2020. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Prelude Capital Management reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 7,095 Moderna shares in Q1 2026, an estimated $209K.
  • Prelude Capital Management first reported a position in Moderna in Q4 2018 and held it in 7 quarters.
  • Prelude Capital Management's Moderna position peaked at $1.03M in Q4 2020.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.